Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 14-93 

AC x 4 followed by CMF x 3 with or without a chemotherapy-free interval, +/- tamoxifen vs. toremifene for post/perimenopausal patients with node positive breast cancer who are not suitable for endocrine therapy alone

DESIGN

Desgin Trial 14-93

Results & Publications


Publications

Study Chairs
Dr. Olivia Pagani - Mendrisio, Switzerland
Dr. Edda Simoncini - Brescia, Italy

Statistician
Shari Gelber

Trial Coordinator
Holly Shaw

Data Managers
Tara Scolese, Dawn Weinbaum

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg10-15@fstrf.org

Date of Activation
May 1993

Date of Closure
August 1, 1999

Targeted Accrual
884 patients

Final Accrual
969 patients


Results Publications Results & Publications
Other Pathology


News

13.10.2014:
The next IBCSG Annual Meeting will take place in Vienna, Austria on March 21st and 22nd, 2015 in

13.10.2014:
Breast Cancer Conference BCC 2015 18 - 21 March 2015 / Vienna / Austria  

01.10.2014:
Benefiz-Gala mit Anton Mosimann Mittwoch 1. Oktober 2014 18.30 Uhr AURA, Bleicherweg 5, 8001 Zürich

All News

 
  Print